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Ten recombinant adenoviruses expressing either fragments of 1135, 1587, or 3329 nt or the full-length spike gene of
transmissible gastroenteritis coronavirus (TGEV) have been constructed. These recombinants produce S polypeptides with
apparent molecular masses of 68, 86, 135, and 200 kDa, respectively. Expression of the recombinant antigen driven by Ad5
promoters was inhibited by the insertion of an exogenous SV-40 promoter. Most of the recombinant antigens remain
intracytoplasmic in infected cells. All the recombinant-directed expression products contain functional antigenic sites C and
B (Gebauer et al., 1991, Virology 183, 225–238). The recombinant antigen of 135 kDa and that of 200 kDa, which represents
the whole spike protein, also contain antigenic sites D and A, which have previously been shown to be the major inducers
of TGEV-neutralizing antibodies. Interestingly, here we show that recombinant S protein fragments expressing only sites C
and B also induced TGEV-neutralizing antibodies. The chimeric Ad5–TGEV recombinants elicited lactogenic immunity in
hamsters, including the production of TGEV-neutralizing antibodies. The antisera induced in swine by the Ad5 recombinants
expressing the amino-terminal 26% of the spike protein (containing sites C and B) or the full-length spike protein, when
mixed with a lethal dose of virus prior to administration to susceptible piglets, delayed or completely prevented the induction
of symptoms of disease, respectively. q 1995 Academic Press, Inc.
INTRODUCTION immune response to coronaviruses (Spaan et al., 1990;
Enjuanes and Van der Zeijst, 1995): the spike protein (S)
Transmissible gastroenteritis coronavirus (TGEV) in-
(Buchmeier et al., 1984; Cavanagh et al., 1986; Daniel et
fects the enteric and respiratory tissues of newborn pig-
al., 1993; Daniel and Talbot, 1990; Koolen et al., 1990),
lets resulting in mortality of nearly 100% (Saif and Wesley, the membrane protein (Fleming et al., 1989; Laude et
1992). Protection of newborn animals from TGEV infec- al., 1992; Welch and Saif, 1988), and the nucleoprotein
tion requires the induction of secretory IgA in milk. Previ- (Buchmeier et al., 1984; Laude et al., 1992; Lecomte et
ous studies have shown that precursors of mucosal IgA al., 1987; Nakanaga et al., 1986; Talbot et al., 1984; Wes-
plasma cells originate in lymphoepithelial structures in seling et al., 1993). The study of the induction of protec-
the gastrointestinal and respiratory tracts. These precur- tive immunity to TGEV has focused on S protein because
sor cells switch to IgA production in gut- or bronchus- it is the major inducer of TGEV-neutralizing antibodies
associated lymphoepithelial tissues and migrate to dis- (Delmas et al., 1986; Jime´nez et al., 1986; Laude et al.,
seminated mucosal effector sites, including gastrointesti- 1992) and it mediates binding of TGEV to its cellular
nal and upper respiratory tracts, as well as to exocrine receptor (Sun˜e´ et al., 1990; Godet et al., 1994). A correla-
tissues such as the mammary gland. Recombinant hu- tion between the antigenic and the physical structure of
man adenovirus 5 (Ad5) has efficiently been used to in- S protein has been established (Delmas et al., 1986;
duce protection against viral infections (Berkner, 1988; Jime´nez et al., 1986; Sun˜e´ et al., 1990). Site A is also
Graham and Prevec, 1992). We have reported that Ad5 involved in the induction of in vivo protection (De Diego
infects mucosal tissues of swine (Torres et al., 1995), et al., 1992), but the precise roles of the different anti-
indicating that recombinant adenoviruses might be used genic sites in eliciting resistance to TGEV are unknown
to induce mucosal immunity against TGEV. Helper-inde- (Enjuanes and Van der Zeijst, 1995).
pendent Ad5-based vectors with the capacity to express In this paper we describe 10 Ad5–TGEV recombinants
foreign genes of up to 4.9 kb have been developed (Bett expressing either full-length TGEV spike protein or three
et al., 1993). truncated amino-terminal fragments of this protein.
Several viral proteins are important for inducing an These recombinants induced immune responses in ham-
sters and swine which neutralized TGEV infectivity. In
addition, we demonstrate that porcine serum from Ad–1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 341-585 45 06. E-mail: LEnjuanes@Samba.CNB.UAM.ES. TGEV-immune animals protected swine from TGEV infec-
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tion. Finally, we show that virus-neutralizing antibodies tains the 3 *-end of Ad5 from the XhoI site at 70 map
units (m.u.) with a deletion of the XbaI D fragment fromare induced in the milk of Ad–TGEV-immune hamsters.
78.5 to 84.3 m.u. within the Ad5 E3 coding region. Plasmid
pAB14 also contains the 3 *-end of Ad5 from map unit 70MATERIALS AND METHODS
to 100 with a 2685-nucleotide deletion in the E3 coding
Eukaryotic cells and viruses region. Plasmid pFG173 contains a deletion of essential
sequences to the left of E3 in the Ad genome that rendersThe epithelial swine testicle (ST) cell line (McClurkin
it unable to produce infectious Ad5 (Bett et al., 1993;and Norman, 1966) and human 293 cells which constitu-
Hanke et al., 1990; Mittal et al., 1993).tively express the 5*-end 11% of the Ad5 genome (Gra-
ham et al., 1977) were used to grow the recombinant
Construction of recombinant vectorsadenoviruses. PUR46-MAD strain of TGEV (Sa´nchez et
al., 1990) was cloned, sequenced, and used as a source The general procedure followed to construct recombi-
of the S gene (Gebauer et al., 1991). Neutralization of nant Ad5 viruses expressing TGEV S gene fragments
TGEV was performed by incubating serial 10-fold dilu- (Ad–TS) is summarized in Fig. 1. S gene sequences were
tions of the virus with a 1/20 dilution of the antibody at flanked by SV-40 Pr and polyadenylation sequences
377 for 30 min, and the virus–antibody mixture was plated when indicated (Fig. 2), by subcloning them into plasmid
on ST cells as previously described (Correa et al., 1988). pSV2X3 or pSV2X4. Cassettes with S gene sequences
The neutralization index (NI) was defined as the log10 of were inserted into the unique XbaI site of the partially
the ratio of the PFU after incubating the virus in the deleted E3 gene on plasmid pFG144K3 or pAB14, both
presence of medium or the indicated antiserum. NI indi- of which include the 3 *-end of Ad5. Alternatively, S gene
ces are determined rather than titers since in the first fragments were removed from the original plasmid or
procedure virus–antibody mixtures are evaluated in the from pSV2X3-TS vectors without SV-40 Pr signal, or with-
plaque assay without further dilution of the antibody, pro- out both Pr and polyadenylation sequences, using the
viding highly reproducible results and information about restriction endonucleases indicated in Fig. 1. In this case,
the potency of the antibody (the titer reduction expressed fragment ends were blunted with Klenow and T4 DNA
in logarithmic units rather than the ability of the serum polymerase and cloned into the XbaI site of pFG144K3
to neutralize a few PFU). or pAB14 plasmids that were blunted and dephosphory-
Ad5 strain dl309 contains a small deletion from 83 to lated according to standard procedures (Maniatis et al.,
85 map units and an unknown substitution in the E3 1989). Each of these plasmids is noninfectious by itself,
region (Jones and Shenk, 1979). pFG140 is an infectious but can generate infectious virus following cotransfection
circularized form of Ad5 dl309 carrying a 2.2-kb DNA of 293 cells along with a plasmid, pFG173, which con-
insert (pMX2) encoding ampicillin resistance (Apr) and a tains the 5*-end of Ad5 (Fig. 1) (Graham and Prevec,
bacterial origin of replication. Plasmid pFG140 was used 1992; Hitt et al., 1995, 1994). This results in the rescue
as positive control for infectious Ad5 DNA (Graham et of genes cloned into the E3 region of viral vectors. Co-
al., 1988). transfection was performed essentially as described us-
ing the calcium phosphate precipitate technique (Gra-
Plasmids and bacteria ham and van der Eb, 1973). After 8 to 15 days, plaques
were isolated and expanded, and viral DNA was ana-
The TGEV S gene was cloned into Bluescript (Stra-
lyzed by HindIII restriction enzyme digestion. Viruses
tagene) or pYA plasmids (Smerdou et al., 1995) as pre-
with the expected DNA pattern were plaque purified
viously described (Gebauer et al., 1991). Escherichia coli
three times and the junction of the constructs was se-
DH5 or XL1-blue cells (Stratagene) were transformed
quenced to verify the expected primary structure. Recom-
with newly constructed plasmids by electroporation
binants Ad–TS01 and Ad–TS02 are identical to recombi-
(Dower et al., 1988). Plasmid DNA was prepared by the
nants Ad–TS5 and Ad–TS6, respectively, except that the
alkaline lysis method (Birnboim and Doly, 1979) and puri-
first two were constructed using cloning vector pAB14
fied by CsCl–ethidium bromide density gradient centrifu-
with the large deletion on E3 gene, while in the construc-
gation. S gene fragments or the full-length S gene were
tion of the second pair of recombinants plasmid
flanked either by SV-40 promoter (Pr) alone or by both
pFG144K3, with the smaller deletion on E3, was used.
Pr and polyadenylation sequences, as indicated. S gene
fragments were first subcloned into pSV2X3 or pSV2X4 Immunoprecipitation of S antigens expressed by
plasmids (Prevec et al., 1990). The structures of the three recombinant Ad–TS
key plasmids (pFG144K3, pAB14, and pFG173) used in
the construction of Ad5–TGEV recombinants have been Subconfluent 293 cells grown in Dulbecco’s modified
Eagle medium with 5% horse serum (Gibco Europe) werereported previously (Bett et al., 1993; Mittal et al., 1993).
Plasmid pFG144K3 was derived from pFG144 (Ghosh- infected with Ad–TS recombinants at a multiplicity of
infection (m.o.i.) of 30 PFU per cell. After 1 hr of virusChoudhury et al., 1986) and as essential features con-
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FIG. 1. Construction of plasmid vectors and recombinant adenoviruses carrying S gene. Recombinant plasmids were constructed following
standard procedures (Maniatis et al., 1989). S gene sequences previously cloned into Bluescript(SK0) (Promega) or pYA (Smerdou et al., 1995)
plasmids were excised using the indicated restriction endonucleases and subcloned into pSV2X3 or pSV2X4, in which the S gene sequences were
flanked by SV-40 Pr, polyadenylation sequences, or both. To generate recombinants Ad–TS07, Ad–TS05, Ad–TS9, and Ad–TS06 S gene sequences
were cloned directly into plasmid pFG144K3 or pAB14. S gene sequences either alone or flanked by SV-40 sequences were subcloned into the
XbaI site of pFG144K3 or pAB14, or excised with the indicated restriction endonucleases, blunted using the Klenow polymerase fragment, and cloned
into blunted XbaI unique site of these vectors. Infectious Ad–TS recombinants expressing S protein fragments were generated by cotransfecting 293
cells with pFG144K3-TS or pAB14-TS (which carry S gene sequences from TGEV and pFG173 plasmids). Diagrams are not to scale. The origins of
DNA fragments flanking the S gene are indicated with squares filled with different motifs. Numbers below the bar representing the Ad5 genome
(bottom) indicate map units. mcs, multicloning site; Pr, promoter; An, polyadenylation signal; DE3, deletion in E3 gene; R.E., restriction endonuclease;
TS refers to sequences derived from TGEV spike gene.
adsorption at 377, fresh medium was added and cells dium, and refed with fresh medium containing 50 mCi/ml
of Pro-Mix: L-[35S] in vitro methionine/cysteine labelingwere incubated for 22 hr at 377. Medium was then re-
placed by methionine- and cysteine-free medium con- mix (1 Ci/mmol, Cod. No. SJQ0079, Amersham Ibe´rica).
Cell monolayers were incubated 1.5 hr, detached with ataining 2% dialyzed serum. Cells were incubated for 1 hr
at 377, washed with methionine- and cysteine-free me- rubber policeman, washed with cold phosphate-buffered
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FIG. 2. Structure of the inserts expressed using recombinant Ad5–TGEV. The diagram shows the S gene fragments (light squares) cloned into
the E3 gene of Ad5. Numbers inside the squares indicate the nucleotides at both 5*- and 3*-ends of S gene fragment. When indicated, inserts
were flanked by SV-40 promoter (Pr) (dark squares) and by polyadenylation sequences (white squares). Several S gene fragments were cloned
without either SV-40 Pr or polyadenylation sequences. In the bar shown at the bottom, the positions (nt) of the different antigenic sites of S protein
are indicated. The immunogenicity of the recombinant antigens was determined by evaluating the antiserum induced after administering the
recombinant Ad5 to hamsters by RIA and neutralization, as described under Materials and Methods. Titers in the RIA were expressed as: /, 0 –
1000; //, 1000–3000; ///, 3000–5000; ////, 5000. Results of virus neutralization were expressed as neutralization index: /, 1; //, 1 –
2; ///, 2– 3; ////, 3.
saline, pH 7.2 (PBS), collected by centrifugation at 3000 standard) and Ad–TS recombinants grown under the
same conditions were immunoprecipitated in parallel.rpm for 15 min at 47 in a microfuge, and lysed in RIPA
buffer (50 mM Tris–HCl buffer, pH 7.5, 150 mM NaCl, 1% The same number of infected cells was analyzed for each
recombinant. Similar relative expression levels were ob-Triton X-100, 1% sodium dodecyl sulfate (SDS), and 0.2
mM PMSF). Viscosity was reduced by mixing the tubes tained in many (5) experiments. After protein resolution
in polyacrylamide gel electrophoresis and autoradiogra-in a Vortex mixer and passing the samples through a
0.6-mm needle 10 times. Extracts were centrifuged at phy, the intensity of the immunoprecipitated bands from
Ad–TS extracts was compared with that of the reference30,000 g for 30 min at 47 in a microfuge. Labeled proteins
were immunoprecipitated with TGEV-specific porcine se- [35S]TGEV with known protein concentration (determined
using BCA Protein Assay Reagent, Pierce) to estimaterum which had been preadsorbed several times with
293 cells infected with adenovirus Ad5 dl309. Further the amount of S antigen.
absorption of the antiserum did not eliminate the nonspe-
cific bands. Antigen–antibody complexes were bound Immunofluorescence
to protein A–Sepharose by overnight incubation at 47.
Sepharose beads were washed three times with RIPA ST cells at a density of approximately 1.5 1 105 cells/
cm2 in microslide culture chambers (Miles Scientific)buffer containing 0.2% SDS, and the final pellet was re-
suspended in electrophoresis sample buffer containing were infected with adenovirus Ad140 which contains no
S gene insert, or with Ad–TS recombinants, at a m.o.i.2.5% SDS and 5% 2-mercaptoethanol (Laemmli, 1970).
Samples were boiled for 3 min, the beads were sedi- of 3 PFU/cell. At 24 hr postinfection, cell monolayers were
washed and fixed either with methanol:acetone (1:1) atmented by low-speed centrifugation, and supernatants
were analyzed by polyacrylamide gel electrophoresis 0207 for 15 min or with 4% paraformaldehyde in PBS for
20 min at room temperature. Cells were washed threeand autoradiography. To estimate the amount of protein
expressed by each recombinant different dilutions of su- times with PBS and once with 0.3% bovine serum albumin
(BSA) in PBS for 10 min at room temperature. The cellscrose gradient-purified 35S-labeled TGEV (used as an
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were incubated with hybridoma supernatants containing highest dilution giving a binding threefold higher than
background.a mixture of MAbs 1D.B12, 5B.H1, and 1D.G3 (specific
for S protein sites B, C, and D, respectively) or with MAb Detection of the different antigenic sites in the S pro-
tein fragments, encoded by recombinant Ad–TS, wasH2-19 specific for a 70K Ad5 antigen. After three addi-
tional washings with PBS, cells were covered with a carried out by cRIA using the antiserum elicited in ham-
sters by the different recombinants. The binding of 125I-1:200 dilution of fluoresceinated goat anti-mouse immu-
noglobulins (Cappel Laboratories) in 0.3% BSA in PBS, labeled MAbs to purified TGEV bound to microplates was
performed as previously reported (Correa et al., 1988)incubated for 40 min at room temperature, washed five
times for 10 min each with PBS, and mounted on glyc- with some modifications. Briefly, purified TGEV (0.1 mg/
well) was plated, remaining binding sites were saturatederol–PBS (9:1).
with 5% BSA in PBS, and 125I-labeled MAbs (sp act 1.5
Binding of 125I-labeled MAbs to 293 cells infected 1 107 cpm/mg; 4 1 105 cpm/well) were added and incu-
with recombinant Ad–TS bated for 2 hr at 377 in the presence of fivefold dilutions
of the competitor antiserum prepared in PBS with 0.1%Confluent ST cell monolayers plated on 24-well mi-
BSA. Microplates were washed six times with 0.1% BSAcroplates were infected (m.o.i. 40 PFU/cell) with recombi-
and 0.1% Tween-20 in PBS. Well bottoms were cut andnant Ad–TS viruses. At 24 hr postinfection, cells were
bound radioactivity was determined in a gamma counter.washed with PBS and fixed in methanol:acetone (1:1) for
The percentage of radioactivity bound was determined15 min at 0207 or in 4% paraformaldehyde in PBS for 20
in relation to the radioactivity bound in the absence ofmin at room temperature. Cells were washed three times
competitor MAb. Purified homologous MAbs were usedwith PBS and for 2 hr with 0.5% BSA in PBS. Aliquots of
as positive controls in the cRIA.0.25 ml of 125I-labeled purified MAbs (1 1 106 cpm/well;
1.5 1 107 cpm/mg) (Greenwood et al., 1963) in PBS with
Protection of swine by immune serum0.2% BSA were added to each well and incubated for 1
hr at room temperature, and the cell monolayers were The virulent TGEV strain PUR46-SW11-ST2 (1 1 107
washed six times with PBS. MAb binding was deter- PFU/swine) was mixed with 3 ml of the porcine antiserum
mined by collecting the cells in 0.25 ml of 0.5 N NaOH induced by recombinants Ad–TS8 or Ad–TS06, incu-
and counting the radioactivity in a gamma counter. bated at 377 for 60 min, and administered using a gastric
tube to 2-day-old miniswine born from TGEV-seronega-
Immunization of hamsters and swine tive sows. Inoculated animals were fed three times per
day with milk formula for newborns (Nidina 1, Nestle´)Eight-week-old golden Syrian hamsters were immu-
containing 3 ml of the antiserum. Control animals werenized with infectious Ad–TS recombinants by three
treated following the same procedure but using serumroutes: oral (4 1 108 PFU in 0.2 ml of PBS), nasal (2 1
induced by wt Ad5. Virus titers after 1, 2, and 3 days in108 PFU/0.1 ml), and intraperitoneal (1 1 109 PFU/0.5 ml).
animals challenged with virus treated with control serumThe virus was administered at Days 0, 32, 60, and 90,
and 1, 2, or 5 days postinoculation in animals challengedand orbital plexus puncture bleedings were performed
with TGEV immune serum-treated virus were determinedat Days 0, 32, 47, 87, 105, and 115. Females with highest
in tissue extracts from jejunum and ileum, lungs, mesen-titers of TGEV-specific antibodies were crossed with non-
teric, and mediastinal lymph nodes. Tissue homogeniza-immune males, and 8 days later another dose of the
tion was performed at 47 using an OMNI 2000 homoge-homologous Ad–TS recombinant was administered.
nizer (Omni International).Twenty-four hours after delivery, hamsters were subcuta-
neously administered 10 IU of oxytocin. The milk was
collected 1 hr later by applying vacuum with a syringe. RESULTS
Milk was diluted fourfold in PBS and stored at 0207.
Ad5–TGEV recombinantsOne-month-old swine, from crossing Large White and
Belgium Landrace, were immunized three times at 0, 28, Ten Ad5–TGEV recombinants expressing TGEV S
and 56 days, each time by three routes: oral (1 1 109 gene fragments were constructed using vectors with dif-
PFU), nasal (1 1 109 PFU), and intraperitoneal (1 1 109 ferent deletions on E3 gene or combinations of SV-40
PFU per dose). Serum was collected 14 days after the promoter and polyadenylation signals. Using these re-
last immunization. combinants S protein fragments of four different sizes
were expressed. The recombinants were obtained by
Radioimmunoassay (RIA) and competitive RIA (cRIA)
replacing the E3 gene of the Ad5 genome with S gene
with 125I-labeled MAbs
sequences starting from nt 08 and the first 5*-end 1135,
1587, 3329, or 4341 nt of the S gene. These recombinantsRIA was performed using purified TGEV as antigen
(0.1 mg/well) as previously described (Jime´nez et al., code for fragments of 378, 529, 1109, and 1447 amino
acids (aa) extended from the amino-terminus (Fig. 2). The1986). Titers in RIA were defined as the inverse of the
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faint band (results not shown). Recombinant products
with apparent molecular masses of 68 and 135 kDa (Fig.
3, lanes c and e, respectively) were obtained for recombi-
nant S protein fragments of 378 and 1109 aa, respec-
tively. Recombinants Ad–TS07 and Ad–TS5, both coding
for polypeptides of 529 aa, gave a main band of 86 kDa
and a minor band of 80 kDa (lane d), which probably
corresponds to an underglycosylated form of the antigen
or to a degradation product. The difference between the
expected and the apparent molecular mass of the recom-
binant products suggests that these are heavily glycosyl-
ated, as occurs during S protein synthesis after TGEVFIG. 3. Analysis of the S protein fragments expressed by Ad–TS
infection (Delmas and Laude, 1990). A band with Mr 110Krecombinants. Recombinant antigens expressed by the indicated Ad5–
was also precipitated in cells infected with Ad5 with orTS viruses were metabolically labeled with [35S]methionine, immuno-
precipitated with TGEV-specific antiserum, and analyzed by SDS– without S gene insert (Fig. 3, lanes b to e), but not in
PAGE (Materials and Methods). Specific bands are indicated by arrows. uninfected cells (lane a) suggesting that it was a nonspe-
One or two bands with molecular masses around 60 and 110 kDa were cifically bound Ad5 antigen. This band was not elimi-nonspecifically precipitated in Ad5 virus (without insert)-infected but
nated after extensive serum adsorption with extractsnot in uninfected cells, and probably correspond to Ad5 proteins. Lanes
from Ad5-infected 293 cells.correspond to representative immunoprecipitates from extracts of: a,
uninfected 293 cells; b, cells infected with Ad5 virus with no insert; c,
Ad–TS2 or Ad–TS8; d, Ad–TS07 or Ad–TS5; e, Ad–TS9. Recombinants
Antigen expression levelsAd–TS02, Ad–TS05, and Ad–TS6 give bands in the same position as
that of Ad–TS9 but of lower intensity (not shown). A very faint specific
Recombinant antigen expression levels were esti-band was observed after immunoprecipitation of extracts from cells
mated by immunoprecipitation with TGEV-specific anti-infected with recombinant Ad –TS01 and Ad–TS06 (not shown). M,
molecular weight markers (numbers indicate kDa 1 1003). serum using extracts from 293 cells infected with the
chimeric Ad–TS viruses (Fig. 3). The amount of S protein
was based on the comparison of band intensity after
last product represents the full-length spike protein. The immunoprecipitation and autoradiography of 35S-labeled
constructs were obtained using either plasmid recombinant antigens and reference sucrose gradient-
pFG144K3 or plasmid pAB14 (Fig. 1), with deletions of purified 35S-labeled TGEV with known protein concentra-
1.88 or 2.69 kb, respectively, in E3 (Bett et al., 1993). tion. Both reference virus and recombinant antigens were
Recombinant plasmids were constructed as summarized labeled and analyzed in parallel using the same experi-
(Fig. 1). When indicated, the S gene fragments were mental conditions. Since the distribution of the methio-
flanked by Pr and polyadenylation signals (Fig. 2) by clon- nine and cysteine in the different fragments was similar,
ing them into vector pSV2X3 or pSV2X4. Inserts were no significant correction of band intensity was necessary
subcloned into plasmid pFG144K3 or pAB14 containing in the analysis. The expression levels ranged from 0.1
the 3 *-end half of Ad5. Human 293 cells were cotrans- to 10 mg of S protein per 106 infected cells. Maximum
fected with one of these plasmids and pFG173, which expression levels (5 to 10 mg/106 cells) were obtained
contains almost the entire Ad5 genome with a lethal for recombinants Ad–TS5, Ad–TS8, and Ad–TS07, inter-
deletion across the E3 region. Fully infectious Ad–TS mediate levels (1 to 3 mg/106 cells) for Ad–TS9, Ad–TS2,
viruses were recovered following recombination in co- Ad–TS05, and Ad–TS6, and minimum (around 0.1 mg/
transfected 293 cells. Recombinant viruses were plaque 106 cells) for recombinants Ad–TS01, Ad–TS02, and Ad–
purified. The DNA from all the recombinants gave the TS06. Relative expression levels were highly reproduc-
pattern and sequence expected for each insert by HindIII ible in different experiments. All the recombinants, in-
restriction endonuclease analysis and sequencing of cluding those expressing minimum amounts of antigen,
DNA junctions (results not shown). were also consistently positive in the immunofluores-
After infection of 293 cells with Ad–TS recombinants, cence and 125I binding assays and in the induction of
S protein antigens remained cell associated. Tris buffer TGEV-specific antibodies (see below).
containing 1% SDS was used to solubilize them. The When indicated, the S gene fragment cloned into Ad5
estimated size of recombinant S antigen expressed by was flanked by Pr and polyadenylation signals (Fig. 2).
Ad –TS vectors was evaluated by immunoprecipitation Comparison of the expression levels in constructs with
and representative results are shown (Fig. 3). S polypep- S gene fragments of the same size indicated that Ad5
tides were detected with a polyclonal TGEV-specific por- recombinants made using pFG144K3 plasmids ex-
cine serum. Good specific immunoprecipitation bands pressed higher levels of antigen than those based on
were systematically obtained with all recombinants ex- plasmid pAB14, although in some cases (i.e., recombi-
nant Ad–TS07 compared with Ad–TS5) the level of ex-cept Ad–TS01, Ad–TS02, and Ad–TS06, which gave a
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pression was similar (results not shown). In recombi-
nants with the same E3 deletion it was also observed
that removal of SV-40 Pr yielded Ad–TS recombinants
with higher expression levels (results not shown).
Cellular location of the S antigens coded by the Ad–
TS recombinants
To study the cellular location of recombinant S antigen,
we used immunofluorescence analysis of ST cells in-
fected with four selected recombinants each coding for
S fragments of different size: 387, 529, 1109, and 1447
(full-length S protein) amino acids. A bright fluorescent
signal was observed in the cytoplasm of methanol–ace-
tone-fixed cells infected with recombinants Ad–TS8, Ad –
TS5, and Ad–TS9 (results not shown). Highest fluores-
cence intensity was seen with TGEV-infected cells and
FIG. 4. Binding of MAbs specific for S protein antigenic sites to STlowest intensity with cells infected with Ad–TS06 recom-
cells infected with Ad–TS recombinants. 125I-labeled MAbs specific forbinant expressing the full-length S protein. In infected
antigenic site C (5B.H1), B (1D.B12), D (1D.G3), and A (6A.C3) (Gebauer
cells fixed with paraformaldehyde processed in parallel, et al., 1991) were incubated on methanol–acetone-fixed ST cells in-
the intensity of the staining was considerably weaker. In fected with the indicated recombinant or with TGEV. Cell monolayers
were washed and the bound radioactivity was determined as indicatedthis case, cells infected with TGEV showed a clear stain-
under Materials and Methods. Mean values have been represented.ing of the plasma membrane, while very weak fluores-
Standard deviations were lower then 25% of the mean in all cases andcence was observed in cells infected with the four Ad –
are not shown.
TS recombinants. When immunofluorescence was per-
formed with a human Ad5-specific MAb (which binds 72K
protein) bright fluorescence was observed on discrete though amino acids 380 to 387 of S protein site D are
areas of the nucleus, but not in the cytoplasm (results coded by recombinant Ad–TS5, this site was poorly rec-
not shown), in contrast to the cytoplasmic fluorescence ognized by MAb 1D.G3 specific for D site on Ad–TS5-
observed with TGEV-specific MAbs. infected cells (Fig. 4). The four antigenic sites were
An estimation of the relative amount of S antigen lo- weakly detected in cells infected by recombinant Ad–
cated in the cytoplasm or accessible on the surface of TS06, probably due to the low replication level of this
Ad5-infected ST cells was determined by studying the recombinant.
binding of 125I-labeled MAb 1D.B12 (site B-specific) to
methanol- or paraformaldehyde-fixed cells (results not Immunogenicity of the recombinants
shown). This MAb was selected because it recognizes
an epitope present in all Ad–TS recombinants. Cells in- Immune responses elicited by the different recombi-
nants were studied by inoculating hamsters both orona-fected with recombinants Ad–TS8, Ad–TS5, and Ad–TS9
permeabilized with methanol–acetone expressed the sally and intraperitoneally (Fig. 5). Seven of the ten re-
combinants summarized in Fig. 2 elicited titers in RIAhighest amount of S antigen, which ranged between 60
and 66% of the amount expressed on ST cells infected higher than 2500 and NI between 1 and 3. The best
inducers of TGEV-neutralizing antibodies were recombi-with TGEV. In cells infected with these recombinants the
binding of site B-specific MAb to exposed antigen was nants Ad–TS8, Ad–TS2, and Ad–TS06, expressing either
the smallest protein fragment or the full-length proteinaround 10% of the binding to cytoplasmic S antigen of
TGEV-infected cells. That is, the amount of S antigen (Fig. 2).
Four recombinants (Ad–TS8, Ad–TS5, Ad–TS9, anddetected on the surface of the infected cells was at least
sixfold lower than that seen in the cytoplasm. The recom- Ad–TS06), each expressing S gene fragments of different
lengths (Fig. 2) were selected to study the induction ofbinant products were not detected in the supernatants
of infected cells, although the media were not concen- an immune response to sites A, B, and D by cRIA (Fig.
6). Site C was not included in the study because thetrated to detect small antigen amounts.
Proper folding of the S protein fragments expressed amino acid sequence PNSD recognized by MAbs spe-
cific for this site (Gebauer et al., 1991) is present in pro-by the four selected recombinants was evaluated by de-
termining the amount of 125I-labeled MAb specific for anti- teins of the immunoglobulin superfamily and other serum
proteins (Correa et al., 1988; I. Correa and L. Enjuanes,genic sites A, B, C, and D bound to infected ST cells (Fig.
4). All recombinants expressed sites C and B. Recombi- unpublished results). Recombinant Ad–TS9 induced an
immune response to antigenic sites B, D, and A (Fig. 6).nant Ad–TS9, in addition, expressed sites D and A. Al-
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FIG. 5. Immune response induced by Ad–TS recombinants in hamsters. Groups of four golden Syrian hamsters were immunized at Time 0 and
at times indicated by arrows (see Materials and Methods) with the indicated recombinants. Sera collected at 0, 32, 47, 87, and, in some cases, at
105 and 115 days postinfection were evaluated by RIA and neutralization against TGEV. Mean serum titers and standard deviation errors are
represented for each time point. The titer by RIA was defined as the inverse of the highest antibody dilution giving a binding three times higher
than the background in the RIA assay. The NI was defined as the log10 of the ratio of the PFU after incubating the virus in the presence of medium
or the indicated antiserum.
All recombinants induced a strong response to site B and milk was determined between Days 1 and 2 during
lactation (Fig. 7). The three recombinants induced anti-(Fig. 6A) which is conformation and glycosylation depen-
bodies in serum with titers in RIA ranging from 5 1 103dent (Gebauer et al., 1991). As expected, site A was only
to 1.5 1 104 and in milk from 2 1 103 to 3 1 103 (Fig.reconstituted by recombinants Ad–TS06 and Ad–TS9,
7A). Serum and milk antibodies neutralized TGEV withexpressing the full-length S protein or the 135-kDa S
NIs ranging from 2 to 4 and around 1, respectively (Fig.antigen, but not by recombinants which do not include
7B). As expected, recombinants with no insert did notthe residues implicated in this site (Fig. 6C).
elicit TGEV-specific antibodies. While antibody titers in
Induction of lactogenic immunity by Ad–TS sera decreased with insert size, the NI increased, sug-
recombinants gesting that antibodies to site A contributed significantly
to the neutralization of TGEV.Female hamsters immunized twice with recombinants
Induction of immune response in swine byAd –TS8, Ad–TS9, and Ad–TS06 were crossed with non-
recombinants Ad–TS8 and Ad–TS06immune males and administered a third dose of the ho-
mologous Ad–TS recombinant 10 days before delivery. The Ad–TS8 and Ad–TS06 recombinants expressing
the smallest insert and the full-length spike protein, re-The presence of TGEV-specific antibodies in the sera
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and 5, respectively). To study the potential of these anti-
sera for protection against TGEV, sera induced by these
recombinants were examined for the ability to prevent
TGEV infection. Virulent TGEV (PUR46-SW11-ST2 strain,
1 1 107 PFU/dose) was mixed with the antibody induced
by each recombinant, incubated at 377 for 60 min, and
administered to highly susceptible 2-day-old miniswine.
Virus titers were determined in jejunum and ileum, lungs,
mesenteric, and mediastinal lymph nodes at 1, 2, 3, and
5 days postinoculation. The results (Fig. 8) indicated that
virus titers found in the enteric tissues were between
102 and 103-fold lower when virus was premixed with
antiserum induced by recombinant Ad–TS8 (Fig. 8D), and
very low titers (5 1 102 PFU/g of tissue) of infectious
virus were detected in the small intestine of newborn
pigs that were administered the antibody elicited by re-
combinant Ad–TS06 (Fig. 8F). In contrast, titers ranging
between 7 1 103 and 1 1 107 PFU/g of tissue were
detected in the tissues of control animals to which serum
induced by wt Ad5, used as a control, was administered
(Fig. 8B). In addition, neither mortality nor clinical symp-
toms were observed in animals treated with serum in-
duced by recombinant Ad–TS06 (Fig. 8E), while control
animals presented diarrhea 24–30 hr postinfection and
died around Day 3 postinfection (Fig. 8A).
DISCUSSION
Ten Ad5–TGEV recombinants have been constructed
and screened for their ability to express spike protein
fragments of TGEV. Four recombinants expressing the
full-length spike protein or truncated fragments spanning
different lengths of S protein from the amino-terminus
have been selected, and their ability to induce virus-
neutralizing antibodies was determined. These Ad– TS
viruses induced lactogenic immunity in hamsters, and
the recombinant expressing the full-length S protein elic-
ited antisera that, when mixed with a lethal dose of virus
prior to administration to susceptible piglets, prevented
the induction of disease symptoms.
Helper-independent Ad5 viruses with a deletion in the
E3 gene have been constructed, and the S gene was
inserted into the E3 gene. Two types of Ad5 recombinantsFIG. 6. Antigenic site specificity of the antisera induced in hamsters by
Ad–TS recombinants. The binding to purified TGEV of 125I-labeled MAbs with deletions of 1.88 and 2.69 kb in the E3 gene have
specific for antigenic sites B, D, and A of TGEV S protein (A, B, and C, been used to express S protein, based on plasmids
respectively) was inhibited in a cRIA (see Materials and Methods) by (l) pFG144K3 and pAB14, respectively (Bett et al., 1993).
the homologous unlabeled MAb, by (s) a control antisera with no reactivity
Since the large deletion affected the splicing acceptorto TGEV, or by sera from hamsters immunized with Ad-TS recombinants:
site after gene L4 and most of the E3 gene, it was of(m) Ad–TS8; (j) Ad–TS5; (n) Ad–TS9; (h) Ad–TS06.
interest to determine the comparative levels of expres-
sion in these two plasmids. Expression levels were al-
ways higher using Ad5 viruses with the smaller deletionspectively, were selected to study the induction of TGEV-
neutralizing antibodies in swine. Although the level of in E3, independent of the insert size, suggesting that
removal of the splicing acceptor site after the L4 generecombinant antigen produced in ST cells was high for
recombinant Ad–TS8 and low for Ad–TS06 (Figs. 3 and might have reduced E3 gene expression. Sequences in-
serted without an exogenous polyadenylation signal4), both recombinants induced high titers of TGEV-spe-
cific antibodies in swine as determined by RIA (1 1 104 were successfully expressed, indicating that the polyad-
enylation signal of the E3 gene has probably been used.and 5 1 104, respectively) and by neutralization (NI of 2
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FIG. 7. TGEV-specific antibodies induced by Ad–TS recombinants in the serum and milk of lactating hamsters. Titers in (A) RIA and (B) neutralization
in the serum (light columns) and milk (dark columns) of hamsters immunized with Ad5 virus or the indicated Ad–TS recombinants. Titers in RIA
and neutralization were defined as described in Fig. 5. Mean values of four hamsters have been represented. Standard deviations were lower than
30% in all cases and are not shown.
In general, recombinants with relatively small inserts low levels of S antigen and, accordingly, of all antigenic
sites (A, B, C, and D), probably due to low replication(1135, 1587, and 3329 nt) expressed larger amounts of
S polypeptide than those with larger (4470-nt) inserts. levels. Nevertheless, antigenic sites A and B were prop-
erly folded after infection with Ad–TS06 virus since highThe recombinants with smaller inserts gave Ad5 titers in
cell culture between 3 1 108 and 1 1 109 PFU/ml, while antibody levels against these sites were elicited in ham-
sters, as detected by cRIA (Fig. 6). S protein trimer forma-Ad5–TS virus with an insert of 4470 nt consistently gave
titers lower than 107 PFU/ml. Thus, the level of expression tion easily explains the dichotomy between low expres-
sion levels and high efficiency in eliciting a high immunein these recombinants correlates well with their level of
replication. The three recombinants (Ad–TS8, Ad–TS5, response. S protein trimers (the native form of the glyco-
protein in the virus) probably are more stable and betterand Ad–TS9) with genome sizes lower than 104% of wt
Ad5 were stable after 10 passages, while the recombi- represent the peplomer in the native virion. Although re-
combinant Ad–TS5 contains the sequences coding fornant with a genome size close to 105% of wt Ad5 (Ad –
TS06) was unstable (results not shown). These results site D core (located in S protein from aa 377 to 390)
(Gebauer et al., 1991; Lenstra et al., 1991; Posthumus etare in line with previous work suggesting that the Ad5
virion has the ability to package approximately 105% of al., 1990), it was very weakly detected by site D-specific
MAbs, while sites C and B, also encoded in this recombi-the wt genome length. This value is generally considered
to be the maximum working capacity of the system nant, were well represented. Site D may have been hid-
den by incorrect folding of the S protein in this area.(Ghosh-Choudhury et al., 1986; Berkner, 1988; Bett et al.,
1993). Site A, the major inducer of TGEV-neutralizing antibodies,
was detected in larger amounts after infection by recom-Viruses in which the inserted gene was flanked by an
SV-40 Pr always showed lower expression levels than binant Ad–TS9 (expressing S protein without the mem-
brane anchor domain) than by recombinant Ad–TS06those not flanked by this Pr (Fig. 3). This suggests that
the SV-40 Pr, in the context that has been used in this (which expresses the full-length S protein). This may be
a consequence of the higher expression levels providedwork, is inhibiting and transcription is probably driven
from the nearby Ad5 E3 Pr. The transcription could also by Ad–TS9, since it has been previously shown (Godet
et al., 1991) that the full-length spike forms trimers andbe driven from the major late protein Pr that is located
far to the left at m.u. 16. Similar observations have been reconstitutes site A better than truncated S proteins miss-
ing the membrane anchor domain. In fact, one of the twomade with other Ad5-based vectors containing analo-
gous E3 substitutions (Schneider et al., 1989; Graham major inducers of TGEV-neutralizing antibodies was Ad–
TS06 virus, in spite of the low amount of S protein pro-and Prevec, 1992; Both et al., 1993).
Antigenic sites C, B, D, and A (starting from the amino- duced by this recombinant.
Seven of ten Ad–TS recombinants expressing S frag-terminal end) have been defined on S protein (Correa et
al., 1988; Gebauer et al., 1991). Sequences coding for ments induced TGEV-neutralizing antibodies in ham-
sters. Recombinant Ad–TS8, expressing a truncated formsites C and B were included in all recombinants and, in
fact, S polypeptides with these two sites were detected of S protein spanning 378 aa from the amino-terminus
(which includes sites C and B but not site A), inducedafter infection with all Ad–TS viruses. The recombinant
coding for the full-length S protein (Ad–TS06) expressed virus-neutralizing antibodies. Since site C does not in-
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FIG. 8. Protection of swine with porcine sera elicited by Ad–TS recombinants. TGEV-specific swine antiserum was elicited by administration of
wt Ad5 virus, Ad–TS8, or Ad–TS06 recombinants (see Materials and Methods). The number of swine surviving after the oral administration of 1 1
107 PFU of the virulent strain PUR46-SW11-ST2 of TGEV mixed with antisera induced by (A) wt Ad5 or by the recombinants (C) Ad–TS8 or (E) Ad–
TS06 expressing the 1135 amino-terminal nt or the full-length spike protein, respectively, is shown. The recovery of infectious virus was determined
1, 2, and 3 or 5 days postinfection (when the animals either died or were sacrificed) in the indicated tissue homogenates, in animals administered
the virulent virus with serum from (B) Ad5, (D) Ad–TS8, or (F) Ad–TS06 immune swine. Three groups of five swine were used to follow the survival
rate. The infectious virus was followed in three groups of three animals each. Mean values have been represented. Standard deviations were lower
than 25% in all cases and are not shown.
duce virus-neutralizing antibodies, site B, or neighboring and Van der Zeijst, 1995) or, alternatively, other factors
similarly to those described in mouse hepatitis virus sys-antigenic domains involved in virus neutralization, have
been reconstituted in a functional form. It has been pro- tem (Fazakerley et al., 1992; Yokomori et al., 1993). Re-
combinant adenoviruses expressing only the 378 amino-posed that factors mapping in the S segment which has
been deleted in the porcine respiratory coronavirus terminal residues of the S polypeptide (which are mostly
deleted in PRCV strains) provide partial protection(PRCV) (from aa 21 to 241) (Callebaut et al., 1988; Sa´n-
chez et al., 1990), and more precisely alterations in amino against TGEV. These data indicate that the amino-termi-
nal S protein fragment might be relevant to confer entericacid 219 (or residues close to it) might be involved in the
loss of enteric tropism (Sa´nchez et al., 1992). These fac- tropism by complementing the binding of N-aminopepti-
dase (identified as a major TGEV receptor) to an S proteintors might be the presence of a second receptor binding
site recognized by a putative second receptor (Enjuanes domain mapping close to antigenic site A (Delmas et al.,
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1992; Godet et al., 1994). Another observation supports with higher titers in swine than in hamsters, although
both species were permissive to virus infection. S proteinthis hypothesis. Ad5 vectors have been used to express
the amino-terminal 564 aa of PRCV S protein, resulting has been previously expressed using E. coli (Hu et al.,
1984, 1987) or poxviruses (Pulford and Britton, 1991), butin production of TGEV-neutralizing antibodies (Callebaut
et al., 1994) which did not protect against challenge with TGEV-neutralizing antibodies were only elicited with re-
combinant poxviruses. Expression of S antigenic site D,virulent TGEV (Callebaut and Pensaert, 1995). By con-
trast, the Ad–TS recombinant eliciting antiserum provid- as a fusion protein on the surface of E. coli led to induc-
tion of TGEV-neutralizing antibodies when purified re-ing passive protection against challenge with virulent
TGEV carries S sequences derived from TGEV instead combinant antigen was used as immunogen, but not
when live vector was administered (Bousquet et al.,of PRCV. The presence of 224 aa (from residue 21 to
244) in recombinant Ad–TS06, which are deleted in the 1994). Using Salmonella typhimurium, site D has been
expressed and TGEV-neutralizing antibodies have beenPRCV, might have been critical to achieve the observed
protection. This interpretation is in agreement with the elicited in serum and in mucosal areas using live recom-
binant bacteria (Smerdou et al., 1995) but protection ex-partial protection seeing with the antiserum elicited in
swine by recombinant Ad–TS8, which includes the se- periments using these systems have not been reported.
Ad5 vectors have a high probability of inducing effectivequences deleted in PRCV, but at the same time indicates
that larger spike protein fragments (as those including mucosal immunity against TGEV, since this virus showed
tropism for mucosal tissues in pigs, and the animalssite A) are needed to elicite full protection.
Protection by recombinant adenoviruses expressing S infected with this virus experienced neither respiratory
nor intestinal disorders (Callebaut and Pensaert, 1995;protein fragments lacking site A extends the results re-
cently reported (Tulboly et al., 1994) on S protein expres- Callebaut et al., 1994; Torres et al., 1995).
sion using baculoviruses. These authors showed induc-
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